Trident Texofab Ltd
Trident Texofab Ltd (TTFL) last traded at ₹25.2, a market capitalisation of ₹37.7 crore, on a P/E of 32.5. Over the past 52 weeks the stock has ranged between ₹21.3 and ₹379. Trident Texofab Ltd last reported results for the quarter ended Jun 2026, with sales of ₹26.14 crore and net profit of ₹0.52 crore. Figures are as of 25 Aug 2026 and are not real time.
Trident Texofab Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Trident Texofab Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹26.14 cr, down 6.9% from ₹28.08 cr a year earlier. Net profit was ₹0.52 cr, down 49.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 26.45 | 31.69 | 38.21 | 28.08 | 30.63 | 25.74 | 33.57 | 26.14 |
| Expenses | 26.72 | 29.37 | 36.86 | 26.01 | 28.15 | 24.1 | 34.65 | 24.72 |
| Operating profit | -0.27 | 2.32 | 1.35 | 2.07 | 2.48 | 1.64 | -1.08 | 1.42 |
| OPM % | -1.02% | 7.32% | 3.53% | 7.37% | 8.10% | 6.37% | -3.22% | 5.43% |
| Other income | 2.76 | -0.2 | 0.43 | 0.44 | 0.39 | 0.38 | -0.5 | 0.19 |
| Interest | 1.13 | 1.38 | 0.99 | 0.73 | 0.96 | 0.87 | 0.37 | 0.55 |
| Depreciation | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.38 | 0.38 |
| Profit before tax | 0.95 | 0.33 | 0.38 | 1.37 | 1.5 | 0.74 | -2.33 | 0.68 |
| Tax % | -6.32% | 6.06% | -34.21% | 25.55% | 25.33% | 22.97% | -13.73% | 23.53% |
| Net profit | 1 | 0.3 | 0.51 | 1.02 | 1.13 | 0.57 | -2.01 | 0.52 |
| EPS (₹) | 0.99 | 0.29 | 0.38 | 0.68 | 0.75 | 0.38 | -1.34 | 0.35 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Trident Texofab Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 50 | 84 | 96 | 99 | 122 | 118 | 116 |
| Operating profit | 3 | 5 | 8 | 8 | 7 | 5 | 4 |
| OPM % | 6% | 6% | 9% | 8% | 6% | 4.3% | 3.8% |
| Net profit | 0 | 1 | 2 | 1 | 3 | 1 | 0 |
| EPS (₹) | 0.35 | 0.97 | 2.20 | 1.07 | 1.85 | 0.47 | 0.14 |
TTM is the trailing twelve months to the most recent quarter.
Trident Texofab Ltd growth and returns
- 10 Years
- 6%
- 5 Years
- 19%
- 3 Years
- 7%
- TTM
- -7%
- 10 Years
- 21%
- 5 Years
- 32%
- 3 Years
- -17%
- TTM
- -59%
- 10 Years
- %
- 5 Years
- -6%
- 3 Years
- -27%
- 1 Year
- -90%
- 10 Years
- 6%
- 5 Years
- 5%
- 3 Years
- 3%
- Last Year
- 3%
Trident Texofab Ltd shareholding pattern
Promoters held 32.16% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 57.78% | 46.89% | 35.54% | 32.16% | 32.16% | 32.16% | 32.16% | 32.16% |
| Public | 42.22% | 53.11% | 64.46% | 67.84% | 67.84% | 67.85% | 67.84% | 67.85% |
| No. of shareholders | 6,257 | 5,756 | 5,428 | 5,069 | 4,998 | 5,097 | 5,632 | 5,948 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Trident Texofab Ltd corporate filings
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hardik Desai Family TrustInsider Trading / SASTlow impact
Cruxal's analysis: Trident Texofab Limited's promoter group, Hardik Desai Family Trust, has increased its…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hardik Desai Family TrustInsider Trading / SASTlow impact
Cruxal's analysis: Hardik Desai Family Trust, part of the promoter group of Trident Texofab Limited, has…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hardik Desai Family TrustInsider Trading / SASTlow impact
Cruxal's analysis: Trident Texofab Limited's promoter group entity, Hardik Desai Family Trust, has increased…
Read the full analysis - Pursuant to Regulation 30 read with Schedule III Part A Para A and Regulation 47 of SEBI Listing Regulations, we hereby enclose copies of newspaper advertisement published on 12th August, ....Company Updatelow impact
Cruxal's analysis: Trident Texofab Ltd has fulfilled its regulatory obligation under SEBI LODR by publishing…
Read the full analysis - Outcome of Board Meeting held on 10.08.2026Board Meetingmedium impact
Cruxal's analysis: Trident Texofab Limited reported Q1 FY27 revenue from operations of 26.14 crore, a…
Read the full analysis - Trident Texofab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve un-audited standalone financial ....Board Meetinglow impact
Cruxal's analysis: Trident Texofab Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Trident Texofab Ltd
Cruxal reads every Trident Texofab Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.